Back to top
more

Eiger BioPharmaceuticals, Inc. (EIGR)

(Delayed Data from NSDQ)

$10.50 USD

10.50
381,110

-0.22 (-2.05%)

Updated May 3, 2019 04:00 PM ET

After-Market: $10.53 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.73% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Eiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Eiger BioPharma (EIGR)? Wall Street Analysts Think 493%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Eagle Pharmaceuticals (EGRX) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.07% and 19.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -5.56% and 29.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharmaceuticals (EIGR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -275.76% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases

by Zacks Equity Research

Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.

Eiger (EIGR) Up on Positive Results From Coronavirus Study

by Zacks Equity Research

Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.

Eiger Down on Disappointing Results From Coronavirus Study

by Zacks Equity Research

Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.

Implied Volatility Surging for Eiger BioPharmaceuticals (EIGR) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Eiger BioPharmaceuticals (EIGR) stock based on the movements in the options market lately.

Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%

by Zacks Equity Research

Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Eiger BioPharma (EIGR) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great Pick

by Zacks Equity Research

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?

by Zacks Equity Research

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Will Eiger BioPharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Eiger BioPharmaceuticals

Eiger Completes NDA Submission of Progeria Drug Lonafarnib

by Zacks Equity Research

Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.

What Makes Eiger BioPharma (EIGR) a New Buy Stock

by Zacks Equity Research

Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Eiger BioPharma (EIGR) a New Buy Stock

by Zacks Equity Research

Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Eiger BioPharmaceuticals (EIGR) Enters Oversold Territory

by Zacks Equity Research

Eiger BioPharmaceuticals, Inc. (EIGR) has been on a bit of a cold streak lately

    Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?